Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 861-872

  Liu, X ^a,c   Wu, J ^a,c   Zhang, S ^a,c   Li, C ^b   Huang, Q ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Adenovirus; Conditionally replicative adenovirus (CRAd); Immunotoxin; Replicative deficient adenovirus; Tumor

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; IMMUNOTOXIN; IMMUNOTOXIN E23; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN PE40; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOLECULAR THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL LINE, TUMOR; EXOTOXINS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; POLYMERASE CHAIN REACTION; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 70350090137     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.30     Document Type: Article

References (39)

1. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654.
2. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111.
3. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
4. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525-526.
5. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4377s-4383s.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
7. Lui VW, He Y, Goyal K, Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol Ther 2001; 3: 169-177.
8. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-1393.
9. Shiau AL, Lin YP, Shieh GS, Su CH, Wu WL, Tsai YS et al. Development of a conditionally replicating Pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. Mol Ther 2007; 15: 131-138.
10. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115.
11. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neopla-sia 2001; 6: 393-406.
12. Schade B, Lam SHL, Cernea D, Sanguin-Gendreau V, Cardiff RD, Jung BL et al. Distinct ErbB-2-coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res 2007; 67: 7579-7588.
13. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-962.
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Gold-hirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
17. Kreitman RJ, Pastan I. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998; 31: 53-88.
18. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immuno-toxin therapy of cancer. Nat Rev Cancer 2006; 6: 559-565.
19. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8: 3092-3099.
20. Jin FS, Youle RJ, Johnson VG, Shiloach J, Fass R, Longo DL et al. Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J Immunol 1991; 146: 1806-1811.
21. Fox E, Hwang JJ, Rizvi N, Sing A, Soho C, Marshall JL et al. Phase I study of the combination of the immunotoxin SGN-10 (BR96sFv-PE40) with docetaxel (DOC) in patients (pts) with solid tumors expressing Lewis-Y. Proc Am Soc Clin Oncol 2003; 222 (abstr 891).
22. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 2004; 10: 16-18.
23. Yang AG, Chen SY. A new class of antigen-specific killer cells. Nat Biotechnol 1997; 15: 46-51.
24. Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J et al. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997; 385: 78-80.
25. Huang Q, Zhang XW, Wang H, Yan B, Dewhirst M, Li CY. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 2004; 10: 1439-1445.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2~CT method. Methods 2001; 25: 402-408.
27. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006; 28: 1601-1613.
28. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomo-nas exotoxin. J Biol Chem 1989; 264: 14256-14261.
29. Jinno Y, Ogata M, Chaudhary VK, Willingham MC, Adhya S, Fitagerald D et al. Domain II mutants of Pseudomonas exotoxin deficient in translocation. J Biol Chem 1989; 264: 15953-15959.
30. Hwang J, Fitzgerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129-136.
31. Houchins JP. Immunotoxin-induced apoptosis. Stem cell 2000; 18: 384-385.
32. Jørgensen R, Merrill AR, Yates SP, Marquez VE, Schwan AL, Boesen T et al. Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature 2005; 436: 979-984.
33. Gallant CV, Raivio TL, Olson JC, Woods DE, Storey DG. Pseudomonas aeruginosa cystic fibrosis clinical isolates produce exotoxin A with altered ADP-ribosyltrans-ferase activity and cytotoxicity. Microbiology 2000; 146: 1891-1899.
34. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-1552.
35. Von Der Thusen H, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr~/~ mice. FASEB J 2001; 15: 2730-2732.
36. Wang Y, Yang Z, Liu S, Kon T, Krol A, Li CY et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005; 92: 1414-1420.
37. Ambriovic-Ristov A, Gabrilovac J, Cimbora-Zovko T, Osmak M. Increased adenoviral transduction efficacy in human laryngeal carcinoma cells resistant to cisplatin is associated with increased expression of integrin 0-3 and coxsackie adenovirus receptor. Int J Cancer 2004; 110: 660-667.
38. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847-853.
39. Shieh GS, Shiau AL, Yo YT, Lin PR, Chang CC, Tzai TS et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006; 66: 9957-9966.